Imunon, Inc..
IMNN.US | Research and experimental development on natural sciences and engineering
Imunon, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the treatment of cancer and infectious diseases. Their primary focus is on developing nucleic acid-based immunotherapies. The company's lead product candidate is a DNA-based immunotherapy desig...Show More
Better Health for All
40
Imunon's core business is dedicated to developing immunotherapies for serious conditions like cancer and infectious diseases. Its lead product candidate, IMNN-001, demonstrated a 13-month increase in median overall survival for patients with advanced ovarian cancer in a Phase 2 trial.
1
The company's entire R&D budget of $11.6 million in 2024 is allocated to health improvement, including $1.8 million for IMNN-001 and $1.4 million for the PlaCCine® vaccine initiative.
2
The IMNN-001 Phase 2 trial reported an excellent safety profile with no serious immune-related adverse events, cytokine release syndrome, or systemic toxicity.
3
The company is also developing IMNN-101, a DNA plasmid vaccine for COVID-19, which has shown robust immune responses and protection against live virus, demonstrating a focus on preventative health measures and global health crisis response.
4
Fair Money & Economic Opportunity
0
No evidence available to assess Imunon, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles to assess Imunon, Inc. against any of the KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage was not available.
1
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found in the provided articles to assess Imunon, Inc. against any of the KPIs for Fair Trade & Ethical Sourcing. The articles mention an internal Code of Ethics and Business Conduct for the company's directors, officers, and employees, which guides their interactions with suppliers.
1
However, this internal code does not provide evidence for the percentage of supplier contracts that include enforceable ethical-sourcing clauses, nor does it offer data on fair-trade certifications, audit frequency, traceability, forced or child labor incidents, remediation speed, high-risk materials spend, or supplier diversity spend.
2
Honest & Fair Business
0
No evidence available to assess Imunon, Inc. on Honest & Fair Business.
Kind to Animals
-60
Imunon conducts extensive animal testing, including preclinical animal studies for cancer therapies and vaccine candidates.
1
These studies involve guinea pigs, mice, and non-human primates.
2
For example, one study used 18 non-human primates and 40 mice.
3
While *in vitro* assays are used for immune response and viral neutralization,
4
animal models are consistently employed for efficacy and disease models, indicating that non-animal methods are rarely used for complex endpoints. The company does not explicitly state a formal, comprehensive animal testing policy,
5
but its operations involve routine animal testing. Animal studies are conducted under standard protocols such as IACUC and in accordance with AAALAC International and the Animal Welfare Act.
6
Imunon collaborates with institutions like the National Institute of Allergy and Infectious Diseases (NIAID)
7
and the Koch Institute for Integrative Cancer Research,
8
which involve animal models in their research.
9
,
10
These collaborations are not explicitly focused on developing industry-wide animal-free testing standards. The company's R&D expenses were $11.3 million in 2023 and $11.7 million in 2022,
11
but there is no specific breakdown of investment in animal-free technologies, suggesting less than 1% of the R&D budget is allocated to such alternatives.
No War, No Weapons
0
No evidence available to assess Imunon, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, concrete data points related to Imunon, Inc.'s environmental performance or planet-friendly business practices are available in the provided articles.
1
The articles primarily focus on the company's business description, leadership, and financial filing dates, explicitly stating that sustainability data or quantitative metrics for environmental performance are not provided or available.
2
Respect for Cultures & Communities
0
No evidence available to assess Imunon, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Imunon, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-30
Imunon, Inc. has set a quantitative waste reduction goal of 20% by 2025.
1
This target specifically focuses on recycling and reducing single-use plastics within its clinical trials.
2